Official Twitter for Orphazyme. Pioneering a new kind of treatment for neurodegenerative orphan diseases. See our community guidelines: http://bit.ly/3uapRYr
Location: Denmark, Capital Region of Denmark, Copenhagen
Total raised: $41.84M
Founded date: 2009
Investors 4
| Date | Name | Website |
| - | Idinvest P... | idinvest.c... |
| - | Kurma Part... | kurmapartn... |
| - | ALS Invest... | alsinvestm... |
| - | Life Scien... | lspvc.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.02.2015 | Series B | $22.67M | - |
| 09.09.2011 | Series A | $19.16M | - |
Mentions in press and media 9
| Date | Title | Description |
| 16.05.2025 | Camurus: A New Chapter in Biopharmaceutical Leadership and Growth | In the world of biopharmaceuticals, change is the only constant. Camurus, a Swedish company, is no stranger to this reality. Recently, it appointed Anders Vadsholt as its new Chief Financial Officer (CFO). This decision marks a pivotal mome... |
| 14.05.2025 | Camurus appoints Anders Vadsholt as Chief Financial Officer | Camurus appoints Anders Vadsholt as Chief Financial Officer Wed, May 14, 2025 08:00 CET Report this content Lund, Sweden — 14 May 2025 — Camurus (NASDAQ STO: CAMX) today announced that Anders Vadsholt has been appointed as Camurus’ Chief Fi... |
| 08.07.2024 | Danish pole position among best Nordic life science stocks in H1 | Danish pole position among best Nordic life science stocks in H1 Mon, Jul 08, 2024 07:45 CET Report this content The first six months of 2024 have passed and it is time to swap the ergonomically designed office chair for a sunbed At BioStoc... |
| 19.07.2019 | Seer adds ex-FDA chief Mark McClellan to the board; Hercules Capital makes it official for new CEO Scott Bluestein | Mark McClellan → On the same day it announced a $17.5 million Series C, life sciences and health data company Seer unveiled that it had lured former FDA commissioner and ex-CMS administrator Mark McClellan on to its boar... |
| 19.08.2015 | Rare disease companies must compete for clinical trial participants | This could be a real blow for patient communities, who have been the driving force behind bringing rare disease to the attention of biopharma companies. “This is a critical juncture for our community,” Nadine Hill, executive director of the... |
| 11.02.2015 | Orphazyme Completes €20M Series B Financing | Orphazyme ApS, a Copenhagen, Denmark-based developer of novel therapeutics for the treatment of rare and genetic diseases, completed a €20m Series B financing round. The round was led by Kurma Partners, with participation from and Idinvest ... |
| 09.09.2011 | Orphazyme Completes €14M Series A Financing | Orphazyme ApS, a Copenhagen, Denmark-based biopharmaceutical company that develops innovative medicines for the treatment of a family of genetic disorders called lysosomal storage diseases, completed a €14m Series A financing round. Partici... |
| 27.03.2011 | Orphazyme Raises DDK 22M in Seed Financing | Orphazyme Aps, a Copenhagen, Denmark-based company that develops therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, raised DDK 22m in seed financing. Investors include new backer Sunstone ... |
| - | Rare disease companies must compete for clinical trial participants | As companies turn to rare disease as primary targets for drug development, they’re starting to hit a snag: It’s hard to find a sufficient patient population to test their drugs and, interestingly, must vie against one another to get access ... |